A reference dataset on New Jersey independent pharmacy transactions — multiples, prescription file valuation, PBM and DIR fee pressure, SBA financing trends, time-to-close, and the consolidation wave reshaping NJ retail pharmacy. Updated quarterly. Free to cite under CC BY 4.0.
Estimated active independent retail pharmacies in New Jersey as of Q1 2026.
Source: NJ Division of Consumer Affairs, Board of Pharmacy active license registry; National Community Pharmacists Association (NCPA) state data.Combined chain (CVS, Walgreens, Rite Aid successors), grocery (ShopRite, Stop & Shop), and independent retail outlets.
Source: NJ DCA Board of Pharmacy 2025 license report.NJ independents have declined approximately 14% over six years, accelerated by Rite Aid's 2023–24 bankruptcy and PBM reimbursement compression.
Source: NCPA Digest 2025, NJ DCA license trend data.Median annual prescription count per independent pharmacy in NJ. Range: 18,000 (low) to 145,000 (high-volume specialty/long-term-care).
Source: NCPA Digest 2025; broker transaction data.NJ pharmacy ownership is concentrated in two distinct buyer profiles: PBM-aligned chain consolidators (CVS, Walgreens, Kroger pharmacy units) and independent operators — often immigrant-owned multi-generational family businesses concentrated in Bergen, Hudson, Essex, Passaic, and Middlesex Counties. The independent population includes specialty (compounding, infusion, fertility), long-term-care (LTC), and traditional retail.
The 2023–2024 Rite Aid bankruptcy reshuffled NJ pharmacy real estate: 78 closed Rite Aid locations across the state created opportunity for both chain expansion and independent purchase of patient files. NJ remains an attractive market for acquisition due to dense population, strong third-party reimbursement infrastructure, and the maturing baby-boomer ownership cohort approaching retirement.
Pharmacy valuations use a different framework than other retail businesses. The two dominant methods:
| Pharmacy type | EBITDA multiple | Rx file value | Typical EV |
|---|---|---|---|
| Single-store independent retail (low-volume, <30K Rx/yr) | 2.5–3.5x | $5–$8 / Rx | $200K–$600K |
| Single-store independent retail (mid-volume, 30K–75K Rx/yr) | 3.5–5.0x | $8–$14 / Rx | $700K–$1.8M |
| Single-store independent retail (high-volume, 75K+ Rx/yr) | 4.0–5.5x | $10–$16 / Rx | $1.5M–$3.5M |
| Long-term-care (LTC) pharmacy | 5.0–7.0x | $15–$22 / Rx | $2M–$8M+ |
| Specialty / compounding pharmacy | 6.0–8.5x | $25–$60 / Rx | $3M–$15M+ |
| Multi-store NJ chain (3–6 stores) | 5.5–7.5x | $12–$18 / Rx | $5M–$25M |
For a chain acquirer or independent buyer purchasing a Rx file in isolation, the file value depends on six factors that materially shift per-script pricing:
Median per-prescription valuation across NJ independent file-only sales tracked 2023–2025.
Source: Nexus Bridge transaction database; NCPA Digest 2025.Long-term-care pharmacy files trade at a 60–70% premium over equivalent retail file volume due to recurring institutional patient base.
Source: IBBA Q-Market Pulse Healthcare 2025; broker transaction data.The single largest valuation question NJ pharmacy buyers ask: what is the pharmacy's normalized DIR fee burden, and how is it trending?
Direct and Indirect Remuneration (DIR) fees are post-point-of-sale fees that PBMs (CVS Caremark, Express Scripts, OptumRx) claw back from pharmacies, often retroactively. Historically, NJ independents have lost 3–7% of gross revenue to DIR fees, with the effect concentrated in Medicare Part D scripts.
The CMS DIR fee reform finalized for 2024 moved DIR fees to point-of-sale rather than retroactive collection. In practice, this:
For NJ pharmacy sales in 2026, expect buyers to:
The SBA 7(a) loan program is the dominant acquisition financing mechanism for NJ pharmacy purchases under $5M. Key 2026 parameters:
NJ pharmacy buyers using SBA 7(a) typically include: licensed NJ pharmacists transitioning from employee to owner; immigrant-pharmacist buyers from outside-NJ markets; and small group buyers (2–3 pharmacist partners). Roughly 60% of NJ independent pharmacy sales under $3M close with SBA financing in some structure.
| Phase | Duration | Activity |
|---|---|---|
| 1. Preparation | 4–8 weeks | Financial normalization, DIR analysis, lease review, transition planning, valuation memo, CIM preparation. |
| 2. Buyer outreach | 4–10 weeks | Confidential outreach to chain acquirers, regional independents, specialty buyers, and qualified pharmacist-purchasers. |
| 3. LOI and exclusivity | 2–4 weeks | Negotiate LOI; agree on price, structure, exclusivity period (typically 60–90 days). |
| 4. Due diligence | 6–10 weeks | Financial QofE, lease and license verification, NABP compliance review, controlled-substance ordering review, payer contract review. |
| 5. SBA underwriting (if applicable) | 8–14 weeks parallel | SBA lender file build, third-party valuation, business credit review, and SBA approval. |
| 6. Definitive agreement and close | 3–6 weeks | APA / SPA negotiation, NJ DCA license transfer filing, payer contract assignments, signing, closing, transition. |
| Total | 5–9 months | From preparation to close. Chain file-only sales close faster (45–90 days post-LOI). |
This dataset is published under the Creative Commons Attribution 4.0 International License (CC BY 4.0). You may quote, adapt, or redistribute the data with attribution.
Working on a story about pharmacy consolidation, NJ independents, or PBM/DIR reform? Email Steven directly or call (201) 400-9827 — quoted same-day for credentialed journalists.
If you operate an NJ independent pharmacy and are considering a sale in the next 12–36 months, we offer free, confidential valuations — including a payer-mix and DIR-normalization analysis — with a two-week turnaround.